Drug Profile
Research programme: anti-viral therapeutics - Evotec SE/Haplogen
Alternative Names: TargetPicVLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Haplogen
- Developer Bayer; Evotec SE; Haplogen
- Class Antivirals; Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Viral infections
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in Austria
- 28 Feb 2021 No recent reports of development identified for research development in Viral-infections in Austria
- 28 Feb 2021 No recent reports of development identified for research development in Viral-infections in Germany